Загрузка...
Future Directions in Myelodysplastic Syndrome: Newer Agents and the Role of Combination Approaches
Myelodysplastic syndrome (MDS) is not a single disease, but a collection of hematopoietic disorders that require newer strategies. Currently, azacitidine, decitabine, and lenalidomide are approved by the US Food and Drug Administration for the treatment of MDS. A recent study demonstrated an improve...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2727156/ https://ncbi.nlm.nih.gov/pubmed/18813208 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|